Temozolomide in Treating Patients With Solid Tumors That Have Spread to the Brain

PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

October 31, 2000

Primary Completion Date

April 30, 2002

Study Completion Date

April 30, 2002

Conditions
Metastatic Cancer
Interventions
DRUG

temozolomide

Administered in a fasting state, once a day for 6 weeks followed by 4 weeks of rest. Cycles may be repeated every 10 weeks until patients have evidence of progressive disease, intolerable toxicity or unwillingness to continue therapy. Daily dose: 75mg/m2.

Trial Locations (1)

90095-1781

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Schering-Plough

INDUSTRY

lead

Jonsson Comprehensive Cancer Center

OTHER